The role of tissue kallikrein in helicobacter pylori-associated gastric disease
| dc.contributor.advisor | Bhoola, K. D. | |
| dc.contributor.author | Naidoo, Strinivasen | en_US |
| dc.date.accessioned | 2017-11-15T08:16:25Z | |
| dc.date.available | 2017-11-15T08:16:25Z | |
| dc.date.issued | 1999 | |
| dc.description | Submitted in partial fulfilment of the requirement for the Degree of Master of Technology: Biological Sciences, ML Sultan Technikon, Durban South Africa, 1999. | en_US |
| dc.description.abstract | Today, the number one income-generating drugs are remedies prescribed for gastric disorders, in particular dyspepsia. These clinical conditions have a multi-faceted aetiology and pathology of dysfunction. One likely causal factor is the entero-pathogen Helicobacter pylori. It has been shown to be more than just a commensal related to gastric diseases like dyspepsia (80-90% incidence) and duodenal ulcer sufferers (100% incidence), with a total estimated world-wide population infection of 50%. The current therapy offered to dyspepsia sufferers is a triple regimen of an anti-bacterial, an Ir proton-pump inhibitor, and bismuth colloidal salts. | en_US |
| dc.description.level | M | en_US |
| dc.format.extent | 291 p | en_US |
| dc.identifier.doi | https://doi.org/10.51415/10321/2779 | |
| dc.identifier.other | 53730 | |
| dc.identifier.uri | http://hdl.handle.net/10321/2779 | |
| dc.language.iso | en | en_US |
| dc.subject.lcsh | Stomach--Diseases | en_US |
| dc.subject.lcsh | Helicobacter pylori infections | en_US |
| dc.subject.lcsh | Kallikrein | en_US |
| dc.title | The role of tissue kallikrein in helicobacter pylori-associated gastric disease | en_US |
| dc.type | Thesis | en_US |